Supplementary Table S8 Prostacyclin-associated adverse events reported in the study titration and maintenance periods for PAH-CTD subtypes

	Titration		Maintenance	
	Placebo	**Selexipag**	**Placebo**	**Selexipag**
PAH-SSc	**N=91***	**N=77**	**N=75**	**N=64**
Patients with ≥1 PGI_2-associated adverse event n (%)	60 (65.9)	66 (85.7)	40 (53.3)	42 (65.6)
Adverse event n (%)				
Headache	29 (31.9)	41 (53.2)	14 (18.7)	19 (29.7)
Diarrhoea	18 (19.8)	28 (36.4)	13 (17.3)	22 (34.4)
Nausea	18 (19.8)	20 (26.0)	11 (14.7)	9 (14.1)
Vomiting	2 (2.2)	3 (3.9)	1 (1.3)	3 (4.7)
Pain in extremity	2 (2.2)	16 (20.8)	2 (2.7)	9 (14.1)
Pain in jaw	3 (3.3)	14 (18.2)	6 (8.0)	12 (18.8)
Dizziness	9 (9.9)	9 (11.7)	12 (16.0)	10 (15.6)
Myalgia	5 (5.5)	9 (11.7)	4 (5.3)	3 (4.7)
Flushing	4 (4.4)	4 (5.2)	1 (1.3)	3 (4.7)
Arthralgia	4 (4.4)	6 (7.8)	2 (2.7)	5 (7.8)
Musculoskeletal pain	1 (1.1)	4 (5.2)	2 (2.7)	3 (4.7)
PAH-SLE	**N=37**	**N=45**	**N=33**	**N=40**
Patients with ≥1 PGI_2-associated adverse event n (%)	22 (59.5)	39 (86.7)	18 (54.5)	33 (82.5)
Adverse event n (%)				
Headache	9 (24.3)	31 (68.9)	5 (15.2)	19 (47.5)
Diarrhoea	7 (18.9)	12 (26.7)	6 (18.2)	7 (17.5)
Nausea	6 (16.2)	17 (37.8)	4 (12.1)	13 (32.5)
Vomiting	4 (10.8)	15 (33.3)	2 (6.1)	7 (17.5)
Pain in extremity	2 (5.4)	5 (11.1)	-	4 (10.0)
Pain in jaw	1 (2.7)	5 (11.1)	-	5 (12.5)
Dizziness	5 (13.5)	5 (11.1)	6 (18.2)	7 (17.5)
Myalgia	2 (5.4)	5 (11.1)	1 (3.0)	4 (10.0)
Flushing	3 (8.1)	6 (13.3)	2 (6.1)	5 (12.5)
Arthralgia	3 (8.1)	3 (6.7)	1 (3.0)	2 (5.0)
Musculoskeletal pain	-	-	-	-
PAH-MCTD/CTD-other	**N=37**	**N=45**	**N=34**	**N=38**
Patients with ≥1 PGI_2-associated adverse event n (%)	25 (67.6)	38 (84.4)	15 (44.1)	28 (73.7)
Adverse event n (%)				
Headache	18 (48.6)	28 (62.2)	7 (20.6)	17 (44.7)
Diarrhoea	4 (10.8)	14 (31.1)	4 (11.8)	9 (23.7)
Nausea	9 (24.3)	16 (35.6)	3 (8.8)	9 (23.7)
Vomiting	1 (2.7)	10 (22.2)	1 (2.9)	5 (13.2)
Pain in extremity	2 (5.4)	6 (13.3)	2 (5.9)	5 (13.2)
Pain in jaw	3 (8.1)	3 (6.7)	-	2 (5.3)
Dizziness	4 (10.8)	6 (13.3)	4 (11.8)	4 (10.5)
Myalgia	-	6 (13.3)	-	3 (7.9)

Flushing	-	5 (11.1)	-	4 (10.5)
Arthralgia	3 (8.1)	2 (4.4)	1 (2.9)	8 (21.1)
Musculoskeletal pain	2 (5.4)	3 (6.7)	3 (8.8)	2 (5.3)

*Among the patients randomly assigned to the placebo group, two did not receive study treatment and were not included in the safety analysis set.

A patient with multiple occurrences of an adverse event during one treatment period is counted only once in the adverse event category for that treatment and period.

CTD: connective tissue disease; MCTD: mixed connective tissue disease; PAH: pulmonary arterial hypertension; SLE: systemic lupus erythematosus; SSc: systemic sclerosis.